| View |
|
DRP-14467-01
|
Fosfomycin (as trometamol)
|
Fhosmyxx
|
3 g per sachet
|
Powder for Oral Solution
|
Antibacterial
|
Stallion Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
10 January 2024
|
08 September 2028
|
| View |
|
DRP-14484-02
|
Potassium Citrate
|
Aztrate XR Plus
|
1.620 g (15 mEq)
|
Extended-Release Tablet
|
Antiurolithic
|
Cooper Pharma Limited
|
India
|
CLIDP Conversion
|
10 January 2024
|
12 September 2028
|
| View |
|
DRP-14528-02
|
Paracetamol
|
Aemol-1g
|
10 mg/mL (1g/100 mL)
|
Solution for Injection (IV Infusion)
|
Analgesic/Antipyretic
|
Hebei Tiancheng Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
09 January 2024
|
02 October 2028
|
| View |
|
DRP-14528-03
|
Paracetamol
|
Paraflow
|
10 mg/ mL (200 mg/ 20 mL); (500 mg/ 50 mL); (1g/100 mL)
|
Solution for Injection (IV Infusion)
|
Analgesic/Antipyretic
|
Hebei Tiancheng Pharmaceutical Co., Ltd
|
China
|
CLIDP Conversion
|
08 January 2024
|
02 October 2028
|
| View |
|
DRP-2653-21
|
Buclizine Hydrohloride + Vitamin B-Complex + Iron
|
Appebiron
|
Buclizine Hydrochloride 25 mg
Thiamine Mononitrate (Vitamin B1) 10 mg
Pyridoxine Hydrochloride (Vitamin B6) 5 mg
Cyanocobalamin (Vitamin B12) 10 mcg
Ferrous Fumarate (equivalent to 25 mg elemental Iron) 76.06 mg
|
Capsule
|
Vitamins and Mineral
|
Lloyd Laboratories, Inc.
|
Philippines
|
Automatic Renewal (OTC)
|
10 January 2024
|
11 March 2029
|
| View |
|
DRP-4152-02
|
Glimepiride
|
None
|
2 mg
|
Tablet
|
Oral Hypoglycemic (Sulfonylurea)
|
Sapphire Lifesciences Pvt. Ltd
|
India
|
CLIDP Conversion
|
08 January 2024
|
18 December 2027
|
| View |
|
DRP-4164-34
|
Cefuroxime (as Axetil)
|
Levexime-500
|
500 mg
|
Film-Coated Tablet
|
Antibacterial (Cephalosporin)
|
Brawn Laboratories Limited
|
India
|
CLIDP Conversion
|
08 January 2024
|
27 December 2027
|
| View |
|
DRP-4224-04
|
Guaifenesin + Salbutamol (as sulfate)
|
Ventosolv
|
50mg/1mg per 5mL
|
Syrup
|
Expectorant/ Selective Beta-2-adrenoreceptor Antagonist
|
Lloyd Laboratories, Inc.
|
Philippines
|
Renewal
|
29 March 2024
|
28 July 2029
|
| View |
|
DRP-4465-06
|
Amino acids + Sorbitol
|
Gominasol
|
Glycine 760 mg
L-Phenylalanine 533 mg
L-Arginine 500 mg
L-Leucine 490 mg
L-Lysine 430 mg
L-Valine 360 mg
L-Isoleucine 352 mg
L-Aspartic Acid 250 mg
L-Threonine 250 mg
L-Histidine 250 mg
L-Methionine 225 mg
L-Alanine 200 mg
L-Proline 100 mg
L-Serine 100 mg
L-Tryptophan 90 mg
L-Glutamic Acid 75 mg
L-Tyrosine 25 mg
L-Cysteine 10 mg
Sorbitol 5 g
Sodium Bisulfite 50 mg
|
Solution for Infusion (IV)
|
Amino acids
|
Shijiazhuang No. 4 Pharmaceutical Co., Ltd
|
China
|
CLIDP Conversion
|
10 January 2024
|
12 December 2027
|
| View |
|
DRP-4737-02
|
Etoricoxib
|
Akticib
|
60 mg
|
Film-Coated Tablet
|
Coxib
|
XL Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
08 January 2024
|
26 September 2028
|
| View |
|
DRP-5271-06
|
Carboplatin
|
Carbozaritine
|
10 mg/ mL (450 mg/ 45 mL)
|
Solution for IV Infusion
|
Antineoplastic
|
Getwell Pharmaceuticals
|
India
|
Renewal
|
24 March 2024
|
16 April 2029
|
| View |
|
DRP-5317-02
|
Cinnarizine
|
None
|
75 mg
|
Capsule
|
Anti-Vertigo
|
Lloyd Laboratories, Inc
|
Philippines
|
CLIDP Conversion
|
08 January 2024
|
24 December 2028
|
| View |
|
DRP-5499-06
|
Timolol (as Maleate)
|
Timol-P
|
5 mg/mL (0.5% w/v)
|
Ophthalmic Solution
|
Anti-glaucoma (Beta-Adrenoreceptor Blocker)
|
Indiana Ophthalmics
|
India
|
Renewal
|
28 March 2024
|
05 September 2029
|
| View |
|
DRP-5745-01
|
Cefuroxime (as axetil)
|
Cefurex 125
|
125 mg/5 mL
|
Powder for Oral Suspension
|
Antibacterial (Cephalosporin)
|
Zim Laboratories Limited
|
India
|
CLIDP Conversion
|
08 January 2024
|
24 April 2029
|
| View |
|
DRP-6051-25
|
Ketoanalogues + Essential Amino Acids
|
Protek-GFR
|
Calcium-4-methyl-2-oxo-valerate (?-ketoanalogue to
leucine, calcium salt)
101 mg
Calcium-3-methyl-2-oxo-butyrate (?-ketoanalogue to
valine, calcium salt)
86 mg
Calcium-2-oxo-3-phenylpropionate (?-ketoanalogue to
phenylalanine, calcium salt)
68 mg
Calcium-3-methyl-2-oxo-valerate (?-ketoanalogue to
isoleucine, calcium salt)
67 mg
Calcium-DL-2-hydroxy-4-(methylthio) butyrate (?-
ketoanalogue to methionine, calcium salt)
59 mg
L-Lysine Acetate USP 105 mg
L-Threonine USP 53 mg
L-Histidine USP 38 mg
L-Tyrosine USP 30 mg
L-Tryptophan USP 23 mg
|
Film-Coated Tablet
|
Renal Nutrition Therapy
|
Stallion Laboratories Pvt. Ltd.
|
India
|
Renewal
|
19 August 2024
|
13 March 2030
|
| View |
|
DRP-6051-26
|
Ketoanalogues + Essential Amino Acids
|
S-Ket
|
|
Film-Coated Tablet
|
Renal Nutrition Therapy
|
Stallion Laboratories Pvt. Ltd
|
India
|
Renewal
|
04 August 2024
|
13 March 2030
|
| View |
|
DRP-6051-27
|
Ketoanalogues + Essential Amino Acids
|
Alogil
|
Calcium-4-methyl-2-oxo-valerate (?-ketoanalogue to
leucine, calcium salt)
101 mg
Calcium-3-methyl-2-oxo-butyrate (?-ketoanalogue to
valine, calcium salt)
86 mg
Calcium-2-oxo-3-phenylpropionate (?-ketoanalogue to
phenylalanine, calcium salt)
68 mg
Calcium-3-methyl-2-oxo-valerate (?-ketoanalogue to
isoleucine, calcium salt)
67 mg
Calcium-DL-2-hydroxy-4-(methylthio) butyrate (?-
ketoanalogue to methionine, calcium salt)
59 mg
L-Lysine Acetate USP 105 mg
L-Threonine USP 53 mg
L-Histidine USP 38 mg
L-Tyrosine USP 30 mg
L-Tryptophan USP 23 mg
|
Film-Coated Tablet
|
Renal Nutrition Therapy
|
Stallion Laboratories Pvt. Ltd.
|
India
|
Renewal
|
04 August 2024
|
13 March 2030
|
| View |
|
DRP-6051-28
|
Ketoanalogues + Essential Amino Acids
|
Ketophil
|
Calcium-4-methyl-2-oxo-valerate (?-ketoanalogue to
leucine, calcium salt)
101 mg
Calcium-3-methyl-2-oxo-butyrate (?-ketoanalogue to
valine, calcium salt)
86 mg
Calcium-2-oxo-3-phenylpropionate (?-ketoanalogue to
phenylalanine, calcium salt)
68 mg
Calcium-3-methyl-2-oxo-valerate (?-ketoanalogue to
isoleucine, calcium salt)
67 mg
Calcium-DL-2-hydroxy-4-(methylthio) butyrate (?-
ketoanalogue to methionine, calcium salt)
59 mg
L-Lysine Acetate USP 105 mg
L-Threonine USP 53 mg
L-Histidine USP 38 mg
L-Tyrosine USP 30 mg
L-Tryptophan USP 23 mg
|
Film-Coated Tablet
|
Renal Nutrition Therapy
|
Stallion Laboratories Pvt. Ltd.
|
India
|
Renewal
|
25 July 2024
|
13 March 2030
|
| View |
|
DRP-6700-03
|
Amoxicillin (as trihydrate)
|
Moxeth-D
|
100 mg / mL
|
Powder for Oral Suspension
|
Antibacterial (Penicillin)
|
Sunlovis Pharmaceuticals LLP
|
India
|
CLIDP Conversion
|
10 January 2024
|
18 May 2026
|
| View |
|
DRP-7059-05
|
Etoricoxib
|
Ecoxia-120
|
120 mg
|
Film-Coated Table
|
Selective COX-2 Inhibitor
|
Lloyd Laboratories, Inc
|
Philippines
|
CLIDP Conversion
|
10 January 2024
|
09 May 2026
|